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A Comparison of White and African American Outcomes
from a Three-Arm, Randomized, Phase III Multicenter Trial
of Advanced or Metastatic Non-small Cell Lung Cancer
Coleman K. Obasaju, MD, PhD,* Rafat H. Ansari, MD,† Mark A. Socinski, MD,‡ Ruqin Chen, MS,*
Matthew J. Monberg, MS,** Robert B. Catalano, PharmD,§ Donna M. Marinucci, BS,§
Darla K. Liles, MD, Maria-Jose Ribeiro, MD,¶ Robert L. Comis, MD,§
and Joseph Treat, MD,* for the Alpha Oncology Research Network
Purpose: To investigate the effect of race on the efficacy and safety
of standard chemotherapy doublet regimens in African American
patients, we conducted a subgroup analysis of a phase III random-
ized trial.
Patients and Methods: Chemonaïve patients with a performance
status of 0 or 1 and stage IIIB or IV non-small cell lung cancer were
randomized to arm A: gemcitabine 1000 mg/m2 on days 1 and 8 plus
carboplatin area under the curve 5.5 on day 1; arm B: the same
schedule of gemcitabine plus paclitaxel 200 mg/m2 on day 1; or arm
C: paclitaxel 225 mg/m2 on day 1 plus carboplatin area under the
curve 6.0 on day 1. Cycles were repeated every 21 days up to 6. A
site selection tool identified institutions with potential to recruit a
minority population. Outcome and toxicity data of white and African
American patients were compared.
Results: Of 1135 total patients, 972 were white (85.6%) and 138
were African American (12.2%). Median survival was 8.3 months
for white patients (95% confidence interval [CI]: 7.7–9.3) and 9.1
months for African American patients (95% CI: 8.2–11.1). Response
rates were 29.1 and 29.0%, respectively. Rates of grade 3 or 4
toxicities were comparable. Among African Americans, median
survival was 7.2 months (95% CI: 5.1–10.1) for gemcitabine-
carboplatin (n  47), 10.5 months (95% CI: 7.1–15.4) for gemcit-
abine-paclitaxel (n  42), and 10.2 months (95% CI: 8.5–13.2) for
paclitaxel-carboplatin (n  49).
Conclusion: Whites and African Americans had similar outcomes,
although there was some variability in survival among African
Americans across the three treatment groups.
Key Words: NSCLC, Phase III, African American, Nonplatinum
doublets, Accrual, Race.
(J Thorac Oncol. 2010;5: 993–1000)
The annual burden of non-small cell lung cancer (NSCLC)was estimated in 2007 at 181,000 new cases and
136,000 deaths in the United States.1 At the time of diagnosis,
most patients (80%) have locally advanced stage III or
metastatic stage IV disease and are ineligible for potentially
curative surgery; and 5-year survival is 10% in this patient
population.2,3 Palliative chemotherapy has become standard
therapy for patients with advanced NSCLC, with platinum-
based or nonplatinum doublets producing a modest survival
benefit and improvement in quality of life compared with best
supportive care alone.4–9
Compared with whites, African Americans have a
greater occurrence and worsened prognosis from lung cancer.
In the United States, incidence rates for cancer of the lung
and bronchus are 112.2 per 100,000 among African Ameri-
cans compared with 81.7 per 100,000 among whites.10 Afri-
can Americans are more likely than whites to be diagnosed
with lung cancer of all stages, with the greatest differential
for advanced or metastatic stage disease.11,12 Surveillance
databases indicate that survival for NSCLC of similar stages
is less for African Americans than for whites.13,14 Differences
in outcomes between African Americans and whites have
largely been attributed to disparities in socioeconomic status
and access to health care.15,16 In an analysis of Eastern Cooper-
ative Oncology Group (ECOG) studies, African Americans
presented with greater weight loss and worsened performance
status when compared with non-African Americans, suggest-
ing that diagnosis may occur in later stages of the disease
course.17 When controlling for factors associated with access
to care, patient outcomes by race are similar.18–21
Although participation in cancer clinical trials is low
across all demographic categories, African American accrual
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to trials is especially lower than that of whites.22,23 Disparities
in accrual persist in spite of the National Institutes of Health
Revitalization Act of 1993, which mandated inclusion of a
valid subset of women and minorities in phase III clinical
trials as a condition of National Institutes of Health funding.24
This law was based on the recognition that clinical trial
findings from one population cannot necessarily be extrap-
olated to others. Despite this federal imperative, few ro-
bust subset analyses of trial outcomes by race have been
published. As a result, the optimal treatment of African
Americans and whites with advanced or metastatic NSCLC is
not clear.
The primary objective of the current phase III study
was to compare the outcomes associated with a reference
regimen of paclitaxel and carboplatin to an alternative plati-
num regimen of gemcitabine and carboplatin and a nonplati-
num regimen of gemcitabine and paclitaxel in patients with
advanced or metastatic NSCLC. The overall clinical results
of this trial have been previously reported.25,26 Additional
components of this trial assessed whether the use of a site selection
tool could result in a patient population that more accurately
reflected patient characteristics in the Surveillance Epidemi-
ology and End Results database10 and a retrospective analysis
of whether outcomes from the trial differed by race and if any
treatment-by-race interaction was present.
PATIENTS AND METHODS
Investigative Site Selection
Alpha Oncology (AO) is a subsidiary of the Coalition
of National Cancer Cooperative Groups. This trial used a site
selection tool created by AO with the goal of recruiting a
diverse patient population that accurately represented the
population of the National Cancer Institute’s (NCI’s) Surveil-
lance Epidemiology and End Results database, which is
11.5% African American.10 Six characteristics indicated
that a site was favorable for minority participation: (1) an
organized multimodality approach to lung cancer with dedi-
cated program combining participation in cancer clinical
trials with delivery of cancer treatment, (2) a dedicated
clinical trial support staff that was separate from clinical
support staff, (3) minority representation within the research
staff (investigators and clinical research associates), (4) geo-
graphic locations with representative minority population, (5)
university medical centers or community centers with univer-
sity affiliations, and (6) Active participation in one of the
three NCI-sponsored multimodality cooperative group pro-
grams (including Cancer and Leukemia Group B, ECOG, or
Southwest Oncology Group [SWOG]). In addition to includ-
ing sites with these characteristics, AO targeted a series of
programs toward minority-based community physician prac-
tices with the goal of overcoming misconceptions and mistrust
associated with clinical trial participation. These programs in-
cluded a public awareness campaign and the distribution of
educational brochures.
Patient Selection/Study Design
Detailed information with respect to patient selection
and study design of this trial is included in a separate
publication.25 Briefly, patients with a histologically con-
firmed diagnosis of stage IIIB (with pleural or pericardial
effusion), stage IV, or recurrent NSCLC were enrolled in
this study.27 Mixed tumors were categorized by the pre-
dominant cell type unless small cell anaplastic elements
were present, in which case the patient was ineligible. All
patients were required to be 18 years or older and have
measurable or evaluable disease (according to ECOG solid
tumor criteria); an ECOG performance status of 0 or 1; and
adequate bone marrow reserve (neutrophils 1500/mm3 and
platelets 100,000/mm3), adequate hepatic function (aspar-
tate transaminase5 times institutional upper limit of normal
and serum bilirubin 1.5 mg/dL times institutional upper
limit of normal), and adequate renal function (creatinine
clearance 40 mL/min or serum creatinine 1.5 mg/dL).
Stage IV patients with brain metastases were eligible pro-
vided the brain metastases were, in the opinion of the site
investigator, clinically stable after treatment with surgery or
radiation therapy.
Patients who met all eligibility criteria were randomly
allocated to receive one of the following three treatment
regimens: arm A: gemcitabine 1000 mg/m2 infused over 30
minutes on days 1 and 8 plus carboplatin area under the curve
5.5 over 15 to 30 minutes on day 1; arm B: gemcitabine 1000
mg/m2 infused over 30 minutes on days 1 and 8 plus pacli-
taxel 200 mg/m2 infused over 3 hours on day 1; or arm C:
paclitaxel 225 mg/m2 infused over 3 hours on day 1 plus
carboplatin area under the curve 6.0 over 15 to 30 minutes on
day 1. Treatment cycles for all three treatment arms were
repeated every 21 days for six cycles, or until unacceptable
toxicity or disease progression. At randomization, patients
were stratified by baseline weight loss, stage of disease, and
presence or absence of brain metastasis. In arms B and C,
patients received prophylactic dexamethasone 20 mg orally
12 and 6 hours before paclitaxel infusion, diphenhydramine
50 mg intravenously (or equivalent) 1 hour before pacli-
taxel infusion, and cimetidine 300 mg intravenously (or
equivalent; ranitidine 50 mg or famotidine 20 mg) 1 hour
before paclitaxel infusion. Patients who developed brain
metastases as the only evidence of progressive disease were
able to be treated with whole brain radiation and corticoste-
roids for brain metastases and remained on study. Chemo-
therapy was resumed 2 weeks after the completion of brain
irradiation. However, if the patient failed to meet entry
criteria after radiation therapy, the patient was removed from
the study. No other chemotherapy, immunotherapy, antitu-
mor hormonal therapy (excluding contraceptives and replace-
ment steroids), or experimental medication was permitted
while the patient was on the study, and appropriate supportive
care was provided.
This study was reviewed and approved by an ethical
review board at each participating institution, and it was
conducted in accordance with the precepts established by the
Declaration of Helsinki. Patients who were eligible for par-
ticipation provided written informed consent consistent with
all applicable governing regulations before undergoing any
study procedure or receiving any study drug.
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Statistical Analysis
The sample size for this study was 1134 patients. The
large number of patients accrued in this study allowed for
retrospective statistical analyses of outcomes by specific
patient subgroups. To assess whether a difference in outcome
by ethnicity was present, overall survival (OS), response rates
(RRs), time to progression (TTP), and tolerability results
were compared between whites (non-Hispanic) and African
Americans. Survival and TTP were assessed using the inten-
tion-to-treat population and calculated from the date of ran-
domization to the date of death or documented progression.
The Kaplan-Meier product limit method was used to con-
struct survival and TTP curves and calculate unadjusted
medians.28 RECISTs criteria were used for response evalua-
tion.29 RRs were calculated by summing the number of
patients with complete responses and partial responses, and
clinical benefit rates were calculated by summing the number
of patients with complete responses, partial responses, and
stable disease. Safety was assessed by calculating the per-
centage of patients experiencing grade 3 or 4 toxicities using
NCI Common Terminology Criteria version 2.0.30 All tests
were two-sided.31
To further compare outcomes by ethnicity and test for
potential treatment-by-ethnicity interaction, Cox proportional
hazard models32 and a logistic regression model were created.
The reported multivariate models were cofactor adjusted for
weight loss, gender, performance status, brain metastasis, and
disease stage and included main effects terms for treatment
and ethnicity and a treatment-by-ethnicity interaction term.
RESULTS
Accrual
Between July 2000 and November 2005, 1135 patients
were screened for eligibility/entry into this trial at 105 inves-
tigative sites in the United States. Of these, 972 patients were
white (85.6%), 138 patients were African American (12.2%),
and 25 were of a different ethnicity. Table 1 summarizes
accrual from sites that had 4 of the six characteristics
associated with favorable minority participation. The 12 sites
that had 4 favorable characteristics for minority participa-
tion enrolled 46.6% of patients in the trial, but 74.6% of all
African Americans. The percentage of African Americans at
sites with 4 characteristics for favorable minority partici-
pation was 19.5% compared with 5.6% at all other sites. Nine
of 12 sites with favorable characteristics exceeded the tar-
geted African American accrual representation of 11.5%.
Patient Characteristics
Table 2 compares patient characteristics between white
and African American patients enrolled in the trial. Com-
pared with white patients, African American patients were
younger and a smaller percentage had stage IV disease. The
median age of white patients was 65 years compared with 58
for African American patients. The percentage of patients 70
years or older was 32.1% for whites and 14.5% for African
Americans. The percentage of patients with stage IV or
recurrent disease was 90.8% for whites and 81.9% for Afri-
can Americans. Similar percentages of white and African
American patients were assigned to each treatment group.
Dose Administration
Of the 1110 white or African American patients who
were screened, 48 (4.3%) did not receive any study therapy;
thus, 1052 patients were included in the safety analysis
population. The median number of cycles of chemotherapy
was 4.0 for both white and African American patients, and
the percentage of patients receiving six cycles of chemother-
apy was 34.3% for white patients and 33.1% for African
American patients. Relative dose intensity (percentage of
planned dose that was administered) of gemcitabine (86.8%
versus 89.9%), carboplatin (90.1% versus 97.1%), and pac-
litaxel (98.8% versus 99.0%) were similar in white patients
compared with African American patients.
Efficacy
Table 3 summarizes the main efficacy parameters in the
trial by ethnicity. Median survival was 8.3 months for white
patients (95% confidence interval [CI]: 7.7–9.3) and 9.1
months for African American patients (95% CI: 8.2–11.1).
RRs were nearly identical between the two ethnicities (29.1
and 29.0%, respectively). Median TTP was 4.6 months for
white patients (95% CI: 4.3–5.1) and 4.3 months for African
American patients (95% CI: 3.3–5.7). Kaplan-Meier curves
for OS and TTP by ethnicity are summarized in Figure 1.
Table 4 summarizes a logistic regression model with
response as the outcome variable and two Cox regression
models with OS and TTP as outcome variables, respectively.
Unadjusted efficacy outcomes were similar across strata of
treatments and ethnicities with one notable exception. Afri-
TABLE 1. Accrual from Sites with 4 Characteristics
Favorable for Minority Participation
Site
Total
Accrual,
N  1135
White,
N  972
African
American,
N  138
East Carolina University 24 10 (41.7) 14 (58.3)
VA Medical Center, Atlanta 18 8 (44.4) 10 (55.6)
Temple University Cancer Center 33 11 (33.3) 18 (54.5)
Hahnemann University Hospital, PA 7 3 (42.9) 3 (42.9)
University of Maryland Greenebaum
Cancer Center
22 14 (63.6) 7 (31.8)
Lineberger Comprehensive Cancer
Center, University of North
Carolina, Chapel Hill
48 35 (72.9) 12 (25.0)
Kimmel Cancer Center, PA 24 18 (75.0) 6 (25.0)
South Carolina Oncology Associates 16 12 (75.0) 4 (25.0)
University of Virginia Cancer Center 59 51 (86.4) 8 (13.6)
Loma Linda, CA 31 24 (77.4) 3 (9.7)
Northern Indiana Cancer Research
Consortium
118 104 (88.1) 12 (10.2)
University of Pittsburgh 129 123 (95.3) 6 (4.7)
Total from 12 sites listed above 529 (46.6) 413 (42.5) 103 (74.6)
Total from all other sites 606 (53.3) 559 (57.5) 35 (25.4)
N, number of patients.
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can Americans receiving gemcitabine-carboplatin had the
lowest RR (17.0%), OS (7.2 months), and TTP (3.6 months)
of any strata. Among African Americans, patients receiving
gemcitabine-carboplatin were marginally less likely to expe-
rience a response than patients receiving paclitaxel-carbopla-
tin (17.0% versus 34.7%, p  0.07). In the cofactor adjusted
model of OS, African Americans receiving gemcitabine-
carboplatin had an hazard ratio of 1.40 (compared with
African Americans receiving paclitaxel-carboplatin; 95% CI:
0.92–2.12). The treatment-by-race interaction effect on OS
was marginally significant when comparing gemcitabine-
carboplatin to paclitaxel-carboplatin (p  0.09).
Toxicity
Chemotherapy safety is summarized for whites and
African Americans in Table 5. Rates of grade 3 or 4 hema-
tologic toxicities were comparable, although whites had a
nonsignificantly higher frequency of grade 3 or 4 thrombo-
cytopenia (28.5% versus 21.1%, p  0.08). Rates of nonhe-
matologic events were also generally similar. The rate of
grade 1 to grade 4 gastrointestinal disorders was significantly
greater among whites compared with African Americans
(74.5% versus 64.7%, p  0.02). Within gastrointestinal
disorders, the rates of grade 1 to grade 4 diarrhea (24.5%
versus 16.5%, p  0.05) and grade 1 to grade 4 constipation
(33.1% versus 24.2%, p  0.04) were significantly greater
among whites. When considering only grade 3 or 4 nonhe-
matologic toxicities, differences between ethnicities were not
statistically significant.
DISCUSSION
The primary clinical results from this trial have been
previously presented.25,26 They demonstrated that all three
regimens produced similar efficacy in terms of OS, RR, and
TTP and that each regimen produced a distinct toxicity
profile, with the reference arm of paclitaxel-carboplatin being
associated with more neurotoxicity and alopecia, whereas
the gemcitabine-carboplatin arm was associated with
greater myelosuppression and reduced median dose inten-
sity. The current analysis indicates that African Americans
enrolled in the trial experienced efficacy outcomes that were
similar to whites with slightly different toxicity profiles. This
finding is consistent with previous analyses of ECOG ad-
vanced NSCLC trials.18 Despite the similarities in overall
results between African Americans and whites, there was
some variability in efficacy outcomes by treatment arm
among African Americans.
This trial showed that minority representation in ad-
vanced or metastatic NSCLC trials may be enhanced by
selective targeting of institutions with favorable characteris-
tics as defined by the site selection tool employed by this trial.
Minority patients have been underrepresented in many of the
reported clinical trials defining the evidence-based practice
standard of modern doublets used as front-line treatment for
TABLE 2. Patient Characteristics
Characteristic
White,
N  972
African American,
N  138
Age (yr)
Median 65 58
Range 32, 88 37, 86
Age 70 yr, n (%) 312 (32.1) 20 (14.5)
Gender, n (%)
Male 592 (60.9) 82 (59.4)
Female 380 (39.1) 56 (40.6)
Performance status, n (%)
0 373 (38.4) 42 (30.4)
1 590 (60.7) 96 (69.6)
2 4 (0.4) 0 (0.0)
Brain metastases, n (%) 162 (16.7) 26 (18.8)
Histology, n (%)
Squamous 170 (17.5) 27 (19.6)
Nonsquamous 802 (82.5) 111 (80.4)
Weight loss, n (%)
5% 613 (63.1) 81 (58.7)
5% 359 (36.9) 57 (41.3)
Disease stage, n (%)
IIIB with effusion 89 (9.2) 25 (18.1)
IV or recurrent disease 883 (90.8) 113 (81.9)
Assignment to treatment, n (%)
Gemcitabine-carboplatin 326 (33.5) 47 (34.1)
Gemcitabine-paclitaxel 329 (33.8) 42 (30.4)
Paclitaxel-carboplatin 317 (32.6) 49 (35.5)
N, number of patients; n, number in group.
TABLE 3. Main Efficacy Parameters
Variable
White,
N  972
African American,
N  138
Best overall response, n (%)
Complete response 11 (1.1) 2 (1.4)
Partial response 272 (28.0) 38 (27.5)
Stable disease 328 (33.7) 48 (34.8)
Progressive disease 186 (19.1) 37 (26.8)
Unknown/Not done 175 (18.0) 13 (9.4)
Response rate (CR  PR), n (%) 283 (29.1) 40 (29.0)
(95% CI) (26.3–32.1) (21.6–37.3)
Clinical benefit rate
(CR  PR  SD), n (%)
611 (62.9) 88 (63.8)
(95% CI) (59.7–65.9) (55.2–71.8)
Overall survival
Failed, n (%) 882 (90.7) 129 (93.5)
Censored, n (%) 90 (9.3) 9 (6.5)
Median, mo (95% CI) 8.3 (7.7–9.3) 9.1 (8.2–11.1)
1 yr, % (95% CI) 34.6 (31.6–37.7) 39.1 (30.9–47.3)
2 yr, % (95% CI) 13.0 (10.8–15.2) 11.9 (6.4–17.5)
3 yr, % (95% CI) 6.3 (4.6–8.0) 5.4 (1.2–9.5)
Time to progression
Failed, n (%) 898 (92.4) 134 (97.1)
Censored, n (%) 74 (7.6) 4 (2.9)
Median, mo (95% CI) 4.6 (4.3–5.1) 4.3 (3.3–5.7)
CI, confidence interval; CR, complete response; PR, partial response; SD, stable
disease; N, number of patients; n, number in group.
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TABLE 4. Regression Analyses with Treatment by Race Interaction Effect
Race Subgroup N
Response Rate,
% (95% CI)
Cofactor Adjusted
OR (95% CI) p for OR Treatment  Race Interaction p
White
Gemcitabine/carboplatin 326 26.4 (21.7–31.5) 0.87 (0.61–1.23) 0.44 0.12 comparing gemcitabine/carboplatin
and paclitaxel/carboplatinGemcitabine/paclitaxel 329 31.6 (26.6–36.9) 1.11 (0.79–1.56) 0.55
Paclitaxel/carboplatin 317 29.3 (24.4–34.7) 1.0 (Reference) Reference
African American
Gemcitabine/carboplatin 47 17.0 (7.7–30.8) 0.41 (0.15–1.09) 0.07 0.81 comparing gemcitabine/paclitaxel and
paclitaxel/carboplatinGemcitabine/paclitaxel 42 35.7 (21.6–52.0) 1.09 (0.45–2.64) 0.85
Paclitaxel/carboplatin 49 34.7 (21.7–49.6) 1.0 (Reference) Reference
Race Subgroup n
Median Survival,
mo (95% CI)
Cofactor Adjusted
HR (95% CI) p for HR Treatment  Race Interaction p
White
Gemcitabine/carboplatin 326 8.2 (7.1–9.4) 0.99 (0.84–1.16) 0.87 0.09 comparing gemcitabine/carboplatin
and paclitaxel/carboplatinGemcitabine/paclitaxel 329 8.4 (7.4–9.7) 0.97 (0.83–1.15) 0.75
Paclitaxel/carboplatin 317 8.7 (7.4–9.9) 1.0 (Reference) Reference
African American
Gemcitabine/carboplatin 47 7.2 (5.1–10.1) 1.40 (0.92–2.12) 0.12 0.32 comparing gemcitabine/paclitaxel and
paclitaxel/carboplatinGemcitabine/paclitaxel 42 10.5 (7.1–15.4) 1.14 (0.72–1.80) 0.57
Paclitaxel/carboplatin 49 10.2 (8.5–13.2) 1.0 (Reference) Reference
Race Subgroup n
Median TTP,
mo (95% CI)
Cofactor Adjusted
HR (95% CI) p for HR Treatment  Race Interaction p
White
Gemcitabine/carboplatin 326 4.6 (4.2–5.3) 0.95 (0.81–1.12) 0.570 0.33 comparing gemcitabine/carboplatin
and paclitaxel/carboplatinGemcitabine/paclitaxel 329 4.6 (4.0–5.4) 0.97 (0.83–1.14) 0.723
Paclitaxel/carboplatin 317 5.0 (4.2–5.6) 1.0 (Reference) Reference
African American
Gemcitabine/carboplatin 47 3.6 (2.8–5.3) 1.20 (0.79–1.83) 0.395 0.73 comparing gemcitabine/paclitaxel and
paclitaxel/carboplatinGemcitabine/paclitaxel 42 4.3 (2.1–6.7) 1.02 (0.66,1.57) 0.931
Paclitaxel/carboplatin 49 4.5 (3.2–6.3) 1.0 (Reference) Reference
CI, confidence interval; HR, hazard ratio; n, number in group; OR, odds ratio; TTP, time to progression.
FIGURE 1. Kaplan-Meier estimates of overall survival (A) and time to progression of disease (B).
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patients with advanced NSCLC.8,33–35 In the current trial,
however, African American accrual was 12.2%, greater than
rates achieved by NCI trials from 1991 to 1994 (9.8%)36 and
from 2000 to 2002 (7.4%).23 Based on the accrual observed in
this trial, the site selection tool was effective at ensuring
patient diversity. The current number of sites able to demon-
strate the required number of favorable characteristics is
limited and achievement by additional institutions may fall
outside the monetary infrastructure setup within the tradi-
tional clinical trial system. Previous research has demon-
strated that long-term meaningful improvement in minority
representation must be a multifocal, cooperative effort be-
tween research sponsors, investigators, and the communities
and institutions in which they serve.37,38
In the overall analysis of efficacy parameters, median
survival (8.3 months versus 9.1 months), TTP (4.6 months
versus 4.3 months), and RR (29.1% versus 29.0%) were
similar between white and African American patients, respec-
tively. This is consistent with previous research that suggests
that whites and African Americans who have uniform access
to health care have similar outcomes in advanced NSCLC.18–21
However, there was some indication of a treatment-by-race
interaction, suggesting that the effect of individual treatment
arms was not consistent within African Americans. Among
whites, median survival ranged from 8.2 to 8.7 months by
treatment arm. Among African Americans, median survival
was 7.2 months for gemcitabine-carboplatin, 10.5 months for
gemcitabine-paclitaxel, and 10.2 months for paclitaxel-car-
boplatin. The worsened outcomes associated with gemcitab-
ine-carboplatin and improved outcomes in the other two arms
for African Americans were also observed with RR and TTP
endpoints. The reduced RR associated with gemcitabine-
carboplatin (17.0%) compared with paclitaxel-carboplatin
(34.7%) among African Americans approached significance
(p  0.07) and in a cofactor adjusted Cox model of OS, the
treatment-by-race interaction term was marginally significant
compared with paclitaxel-carboplatin (p  0.09).
Collaborations between SWOG and Japanese institu-
tions have examined the comparability of results of trials
performed in the United States versus Japan among patients
uniformly treated with the same dose and schedule of pacli-
taxel-carboplatin.39–41 In the analyses, US and Japanese pa-
tients had similar characteristics in terms of age, gender,
disease stage, and histology. However, the US SWOG trial
resulted in an OS of 9 months compared with 12 to 14 months
in the Japanese trials.39,40 The authors hypothesized that these
differences may have been a result of genotypic differences,
which were statistically significant between ethnicities.41
There is some indication that the frequency of pharmacog-
enomic biomarkers that predict response to specific chemo-
therapy regimens (such as ERCC1 and RRM1)42 may vary by
ethnicity within the US population.43,44 Similarly, research
indicates that epidermal growth factor receptor mutations are
not uniform across ethnicities,45 and the activity of epidermal
growth factor receptor inhibitors seems to vary across eth-
nicities.46,47 Unfortunately, no pharmacogenomic samples
were collected for analysis in the current trial.
Although the current article addresses methods to in-
crease diversity within clinical trials, it does not address
broader issues of access to screening or treatment. It is
possible that racial disparities in the broader population are
attributable to factors such as disease stage or performance
TABLE 5. Toxicity According to Treatment Group (Safety Population)
Type of Toxicity
White, N  919
African American,
N  133
p for Overall
ComparisonGrade 3 Grade 4 Grade 3 Grade 4
Hematologic events, n (%)
Neutropenia 150 (16.3) 134 (14.6) 27 (20.3) 22 (16.5) 0.20
Febrile neutropenia 26 (2.8) 7 (0.8) 2 (1.5) 0 (0.0) 0.30
Thrombocytopenia 209 (22.7) 53 (5.8) 23 (17.3) 5 (3.8) 0.08
Platelet transfusion 29 (3.2) 1 (0.8) 0.16
Anemia 100 (10.9) 3 (0.9) 16 (12.0) 0 (0.0) 0.77
Red blood cell transfusion 5 (0.5) 0 (0.0) 1.0
Transfusion 46 (5.0) 4 (3.0) 0.39
Nonhematologic events, n (%)
Infection 18 (2.0) 5 (0.5) 3 (2.3) 0 (0.0) 1.0
Sensory neuropathy 59 (6.4) 2 (0.2) 6 (4.5) 1 (0.8) 0.71
Arthralgia (grade 3 or 4) 20 (2.2) 3 (2.3) 1.0
Alopecia (grade 2) 359 (39.1) 57 (42.9) 0.51
Diarrhea (grade 1 to grade 4) 225 (24.5) 22 (16.5) 0.05
Nausea (grade 1 to grade 4) 508 (55.3) 65 (48.9) 0.19
Constipation (grade 1 to grade 4) 304 (33.1) 32 (24.2) 0.04
Fatigue (grade 1 to grade 4) 667 (72.6) 89 (66.9) 0.18
Any nervous system disorder
(grade 1 to grade 4)
546 (59.4) 85 (63.9) 0.35
N, number of patients; n, number in group.
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status at diagnosis or access to health care services. Soon
after the initiation of the current trial, approved therapy for
the second-line setting became available. Information on
poststudy chemotherapy was not collected. Similarities in OS
by race in this trial, however, make it unlikely that second-
line therapy was disproportionately administered by race.
Conclusions from this retrospective analysis are hy-
pothesis generating, not definitive. Differences in African
American outcomes by treatment did not reach statistical
significance nor were treatment arms powered for such an
analysis. The significance of interaction terms within regres-
sion models is often limited because of sample size require-
ments within subgroups.48 Definitive results with respect to
differences in outcome by race require prospectively de-
signed studies. A phase III study of the effectiveness of
pemetrexed by race in the second-line NSCLC setting is
currently accruing. Enrollment will include 200 African
Americans, 200 Asians, 200 Hispanics, and 400 whites.49 A
phase II trial of second-line erlotinib in African Americans is
also currently recruiting patients.50
Minority accrual in advanced or metastatic NSCLC
trials will continue to be of interest. This trial showed that
selective targeting of institutions, combined with other inter-
ventions, can ensure a diverse patient population. Whites and
African Americans generally had similar outcomes in the
current trial, although there was some variability of outcome
among African Americans across the three treatment groups.
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